Compare PRPO & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPO | CCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Managed Health Care |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4M | 32.7M |
| IPO Year | N/A | 1997 |
| Metric | PRPO | CCEL |
|---|---|---|
| Price | $24.67 | $3.88 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 14.5K | 3.5K |
| Earning Date | 11-14-2025 | 10-15-2025 |
| Dividend Yield | N/A | ★ 10.34% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $22,800,000.00 | ★ $31,747,500.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.95 | N/A |
| 52 Week Low | $3.90 | $3.57 |
| 52 Week High | $28.50 | $8.79 |
| Indicator | PRPO | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 47.33 |
| Support Level | $23.92 | $3.81 |
| Resistance Level | $25.62 | $4.38 |
| Average True Range (ATR) | 1.34 | 0.27 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 66.75 | 50.23 |
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.